Navigation Links
Circassia Acquires North American and Japanese Rights to Dopexamine
Date:10/8/2008

Circassia Establishes Commercial-Scale Supply Chain

Circassia to Develop Dopexamine as Part of Proprietary Post-Surgery

Recovery Protocols

OXFORD, England, October 8 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, announced today that it has acquired the US, Canadian and Japanese development and commercialization rights to dopexamine from the international speciality pharmaceutical company Ipsen. Circassia has also entered into agreements with pharmaceutical manufacturers Excella and Hospira to establish a commercial-scale supply chain for the product.

Circassia is developing dopexamine in a new indication as an integral part of proprietary structured protocols designed to dramatically improve patient recovery following a range of high-risk surgeries. This novel approach, named ToleroCare(R), which Circassia has recently patented, combines the use of dopexamine with the administration of intra-venous fluids to improve tissue oxygenation levels during the recovery period after surgery. The precise use of fluids and dopexamine is based on carefully defined parameters such as heart stroke volume and oxygen delivery index.

ToleroCare therapy has already achieved clinical proof-of-concept in a phase II single-blind, randomized, controlled trial in 122 high-risk general surgery patients in the UK. The study showed that significantly fewer patients who received ToleroCare experienced complications in the 30 day period following surgery compared with those on standard treatment (44% vs. 68%; p = 0.003). In addition, ToleroCare patients recovered significantly quicker, staying in hospital for 17.5 days on average compared with 29.5 days (p = 0.001) for those who received standard therapy.

Dopexamine is a beta2 adrenoceptor and dopamine receptor agonist, which is approved in Europe in indications related to heart failure. Dopexamine is not approved for use currently in the US, Canada or Japan.

"ToleroCare has great potential to dramatically improve patients' recovery following major surgery, as well as to significantly reduce costs by shortening the time spent in hospital. With approximately 825,000 high-risk surgical procedures carried out each year in the US, and the high cost associated with hospital stays, ToleroCare is targeting a major market opportunity," said Steve Harris, Circassia's CEO. "Dopexamine provides Circassia with a further phase II clinical-stage development programme that fits well with our outsourced business model. By establishing a commercial-scale supply chain for dopexamine, we are well positioned to rapidly progress ToleroCare to market."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, which includes Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune(R). The company is also developing its ToleroTrans(R) organ anti-rejection technology, which uses a similar approach to down-regulate immune responses in transplant patients. Circassia has a number of ongoing development programmes, with the most advanced against cat-dander allergy in phase II clinical testing.
For more information please visit http://www.circassia.co.uk.

Contacts

Steve Harris Rob Budge

CEO RJB Communications

Circassia Tel: +44(0)1865-760969

Tel: +44(0)1865-784574 Mobile: +44(0)7710-741241


'/>"/>
SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
2. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
3. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
4. Neogen Acquires Kane Enterprises
5. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
6. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
7. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
8. NSF International Acquires David Begg Associates
9. United BioSource Acquires Caro Research, Leader in Simulation Modeling
10. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
11. Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):